New drug combo tested to stop dangerous bleeding disorder
NCT ID NCT07315373
Summary
This study aims to find the safest and most effective dose of the drug zanubrutinib when given with a steroid (dexamethasone) to adults newly diagnosed with immune thrombocytopenia (ITP). ITP is a condition where the immune system attacks platelets, increasing the risk of bruising and bleeding. Researchers will test different doses in 60 participants to see which one best raises and maintains safe platelet counts over 26 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.